These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 24529213)

  • 21. High Absolute Monocyte Count Predicts Poor Clinical Outcome in Patients with Castration-Resistant Prostate Cancer Treated with Docetaxel Chemotherapy.
    Shigeta K; Kosaka T; Kitano S; Yasumizu Y; Miyazaki Y; Mizuno R; Shinojima T; Kikuchi E; Miyajima A; Tanoguchi H; Hasegawa S; Oya M
    Ann Surg Oncol; 2016 Nov; 23(12):4115-4122. PubMed ID: 27364499
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Integration of circulating tumor cell and neutrophil-lymphocyte ratio to identify high-risk metastatic castration-resistant prostate cancer patients.
    Chong W; Zhang Z; Luo R; Gu J; Lin J; Wei Q; Li B; Myers R; Lu-Yao G; Kelly WK; Wang C; Yang H
    BMC Cancer; 2021 Jun; 21(1):655. PubMed ID: 34078304
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients.
    Fan L; Wang R; Chi C; Cai W; Zhang Y; Qian H; Shao X; Wang Y; Xu F; Pan J; Zhu Y; Shangguan X; Zhou L; Dong B; Xue W
    Prostate; 2018 Mar; 78(4):250-256. PubMed ID: 29285775
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use.
    Lorente D; Mateo J; Templeton AJ; Zafeiriou Z; Bianchini D; Ferraldeschi R; Bahl A; Shen L; Su Z; Sartor O; de Bono JS
    Ann Oncol; 2015 Apr; 26(4):750-755. PubMed ID: 25538172
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pretreatment Neutrophil to Lymphocyte Ratio (NLR) Predicts Prognosis for Castration Resistant Prostate Cancer Patients Underwent Enzalutamide.
    Kumano Y; Hasegawa Y; Kawahara T; Yasui M; Miyoshi Y; Matsubara N; Uemura H
    Biomed Res Int; 2019; 2019():9450838. PubMed ID: 30800682
    [TBL] [Abstract][Full Text] [Related]  

  • 26. No significant impact of patient age and prior treatment profile with docetaxel on the efficacy of cabazitaxel in patient with castration-resistant prostate cancer.
    Kosaka T; Hongo H; Watanabe K; Mizuno R; Kikuchi E; Oya M
    Cancer Chemother Pharmacol; 2018 Dec; 82(6):1061-1066. PubMed ID: 30283980
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimal sequencing strategy using docetaxel and androgen receptor axis-targeted agents in patients with castration-resistant prostate cancer: utilization of neutrophil-to-lymphocyte ratio.
    Koo KC; Lee JS; Ha JS; Han KS; Lee KS; Hah YS; Rha KH; Hong SJ; Chung BH
    World J Urol; 2019 Nov; 37(11):2375-2384. PubMed ID: 30734074
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Pretherapeutic Neutrophil-to-Lymphocyte Ratio for Docetaxel-Based Chemotherapy Is Useful for Predicting the Prognosis of Japanese Patients with Castration-Resistant Prostate Cancer.
    Tatenuma T; Kawahara T; Hayashi N; Hasumi H; Makiyama K; Nakaigawa N; Kishida T; Miyoshi Y; Yao M; Uemura H
    Biomed Res Int; 2019; 2019():2535270. PubMed ID: 31781602
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer.
    Maughan BL; Xhou XC; Suzman DL; Nadal R; Bassi S; Schweizer MT; Antonarakis ES
    Prostate; 2015 Nov; 75(15):1814-20. PubMed ID: 26306637
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Platelet-lymphocyte and neutrophil-lymphocyte ratios are prognostic but not predictive of response to abiraterone acetate in metastatic castration-resistant prostate cancer.
    Lozano Martínez AJ; Moreno Cano R; Escobar Páramo S; Salguero Aguilar R; Gonzalez Billalabeitia E; García Fernández R; De La Fuente Muñoz I; Romero Borque A; Porras Martínez M; Lopez Soler F; Cardenas Cánovas E; Ortega Martín I
    Clin Transl Oncol; 2017 Dec; 19(12):1531-1536. PubMed ID: 28718070
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Circulating tumor cells as a biomarker predictive of sensitivity to docetaxel chemotherapy in patients with castration-resistant prostate cancer.
    Okegawa T; Itaya N; Hara H; Tambo M; Nutahara K
    Anticancer Res; 2014 Nov; 34(11):6705-10. PubMed ID: 25368278
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy.
    Halabi S; Lin CY; Small EJ; Armstrong AJ; Kaplan EB; Petrylak D; Sternberg CN; Shen L; Oudard S; de Bono J; Sartor O
    J Natl Cancer Inst; 2013 Nov; 105(22):1729-37. PubMed ID: 24136890
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inflammatory factor-based prognostic risk stratification for patients with metastatic castration-resistant prostate cancer treated with docetaxel.
    Shi X; Fan J; Pei X; Wang Y; Guo G; Yang T; Wang X; He D; Li L
    Andrologia; 2021 Jul; 53(6):e14064. PubMed ID: 33900646
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sequencing of Cabazitaxel and Abiraterone Acetate After Docetaxel in Metastatic Castration-Resistant Prostate Cancer: Treatment Patterns and Clinical Outcomes in Multicenter Community-Based US Oncology Practices.
    Sonpavde G; Bhor M; Hennessy D; Bhowmik D; Shen L; Nicacio L; Rembert D; Yap M; Schnadig I
    Clin Genitourin Cancer; 2015 Aug; 13(4):309-318. PubMed ID: 25743206
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical Impact of the Number of Treatment Cycles in First-Line Docetaxel for Patients With Metastatic Castration-Resistant Prostate Cancer.
    Kongsted P; Svane IM; Lindberg H; Sengeløv L
    Clin Genitourin Cancer; 2017 Apr; 15(2):e281-e287. PubMed ID: 27692811
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer: Post Hoc Analyses of Data from a Phase 3 Trial.
    Mahon KL; Qu W; Lin HM; Spielman C; Cain D; Jacobs C; Stockler MR; Higano CS; de Bono JS; Chi KN; Clark SJ; Horvath LG
    Eur Urol; 2019 Sep; 76(3):306-312. PubMed ID: 30466891
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of the immune-inflammatory indices for patients with metastatic hormone-sensitive and castration-resistant prostate cancer.
    Wang Z; Liu H; Zhu Q; Chen J; Zhao J; Zeng H
    BMC Cancer; 2024 Jul; 24(1):817. PubMed ID: 38978000
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neutrophil-to-Lymphocyte Ratio Predicts Prognosis in Castration-Resistant Prostate Cancer Patients Who Received Cabazitaxel Chemotherapy.
    Uemura K; Kawahara T; Yamashita D; Jikuya R; Abe K; Tatenuma T; Yokomizo Y; Izumi K; Teranishi JI; Makiyama K; Yumura Y; Kishida T; Udagawa K; Kobayashi K; Miyoshi Y; Yao M; Uemura H
    Biomed Res Int; 2017; 2017():7538647. PubMed ID: 28948170
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients.
    Azad AA; Eigl BJ; Murray RN; Kollmannsberger C; Chi KN
    Eur Urol; 2015 Jan; 67(1):23-29. PubMed ID: 25018038
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Survival Outcomes of Concurrent Treatment with Docetaxel and Androgen Deprivation Therapy in Metastatic Castration-Resistant Prostate Cancer.
    Jang HS; Koo KC; Cho KS; Chung BH
    Yonsei Med J; 2016 Sep; 57(5):1070-8. PubMed ID: 27401636
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.